Unknown

Dataset Information

0

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.


ABSTRACT: This study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib.This open-label, multicentre, phase 2 trial of oral linifanib 0.25 mg/kg/day enrolled patients who had prior nephrectomy and adequate organ function. The primary end-point was objective response rate (ORR) per response evaluation criteria in solid tumors (RECIST) by central imaging. Secondary end-points were progression-free survival (PFS), overall survival (OS) and time to progression (TTP). Safety was also assessed.Fifty-three patients, median age 61 years (range 40-80) were enrolled (August 2007 to October 2008) across 12 North-American centres. Median number of prior therapies was 2 (range 1-4); 43 patients (81%) had clear-cell histology. ORR was 13.2%, median PFS was 5.4 months (95% Confidence Interval (CI): 3.6, 6.0) and TTP was the same; median OS was 14.5 months (95% CI: 10.8, 24.1). The most common treatment-related adverse events (AEs) were diarrhoea (74%), fatigue (74%) and hypertension (66%), and the most common treatment-related Grade 3/4 AE was hypertension (40%).Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25 mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials.

SUBMITTER: Tannir NM 

PROVIDER: S-EPMC4167844 | biostudies-other | 2011 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications


<h4>Purpose</h4>This study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib.<h4>Materials and methods</h4>This open-label, multicentre, phase 2 trial of oral linifanib 0.25 mg/kg/day enrolled patients who had prior nephrectomy and adequate organ function. The primary end-point was objective response rate (ORR) per response evaluation criteria in solid tumors (RECIST) by central imaging. Secondary end-poi  ...[more]

Similar Datasets

| S-EPMC3882163 | biostudies-literature
| S-EPMC10166178 | biostudies-literature
| S-EPMC8493486 | biostudies-literature
| S-EPMC4754968 | biostudies-literature
| S-EPMC4647871 | biostudies-literature
| S-EPMC2394342 | biostudies-other
| S-EPMC4453836 | biostudies-literature
| S-EPMC6701190 | biostudies-literature
| S-EPMC4591942 | biostudies-literature
| S-EPMC6669904 | biostudies-literature